You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, T-Cell

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)

Not yet recruiting
  • NK/T Cell Lymphoma
  • +2 more
  • Guangzhou, Guangdong, China
  • +1 more
Jan 12, 2023

NK/T-cell Lymphoma Trial in Shanghai (Positron Emission Tomography/Magnetic Resonance (PET/MR))

Not yet recruiting
  • NK/T-cell Lymphoma
  • Positron Emission Tomography/Magnetic Resonance (PET/MR)
  • Shanghai, Shanghai, China
    Ruijin Hospital
Dec 14, 2022

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

Active, not recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Peripheral T Cell Lymphoma Trial in Zhengzhou (SHR0302)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jun 2, 2023

T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma Trial in Chicago (Fenretinide)

Not yet recruiting
  • T-cell Lymphoma
  • +10 more
  • Chicago, Illinois
    Rush University Medical Center
Oct 24, 2022

Peripheral T Cell Lymphoma Trial in Duarte, Aurora, Philadelphia (Nivolumab and EPOCH)

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Nivolumab and EPOCH
  • Duarte, California
  • +2 more
Jan 6, 2023

Peripheral T Cell Lymphoma Trial in Zhengzhou (Golidocitinib, CHOP Regimen)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jul 18, 2023

Cutaneous T Cell Lymphoma Trial in Chicago (APR-TD011 (RLF-TD011))

Not yet recruiting
  • Cutaneous T Cell Lymphoma
  • APR-TD011 (RLF-TD011)
  • Chicago, Illinois
    Dermatology CTU
Feb 6, 2023

Minimal Residual Disease in Peripheral T-cell Lymphoma

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Tumor biopsy
  • +2 more
  • Boston, Massachusetts
  • +2 more
Dec 19, 2022

Relapsed or Refractory T-cell Lymphomas Trial in Sendai-shi (BMS-986369)

Not yet recruiting
  • Relapsed or Refractory T-cell Lymphomas
  • Sendai-shi, Miyagi, Japan
    Local Institution - 0001
Sep 12, 2023

Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,

Recruiting
  • Cutaneous T-Cell Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • CAR-T Therapy
  • Hefei, Anhui, China
  • +7 more
Jul 31, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma Trial in Taiwan (Chidamide)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma
  • Kaohsiung, Taiwan
  • +4 more
Apr 17, 2023

T Lymphoblastic Leukemia/Lymphoma Trial in Hangzhou (Chidamide)

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • Hangzhou, Zhejiang, China
    The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 7, 2023

Peripheral T Cell Lymphoma, Epigenetic Repression Trial in Tianjin (Chidamide, Azacitidine)

Recruiting
  • Peripheral T Cell Lymphoma
  • Epigenetic Repression
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jul 14, 2023

T Lymphoblastic Leukemia/Lymphoma Trial in Shenzhen (CD7 CAR-T cells)

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • CD7 CAR-T cells
  • Shenzhen, Guangdong, China
    Li Yu
Nov 11, 2022

Cutaneous T Cell Lymphoma, Mycosis Fungoides Trial (Hypericin, Visible Light)

Not yet recruiting
  • Cutaneous T Cell Lymphoma
  • Mycosis Fungoides
  • (no location specified)
May 23, 2023

Skin Barrier and Microbiome of CTCL Patients

Not yet recruiting
  • Lymphoma, T-Cell, Cutaneous
    • Leiden, Netherlands
      Centre for Human Drug Research
    Apr 21, 2023

    Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)

    Recruiting
    • Peripheral T Cell Lymphoma
    • Azacitidine Injection
    • +6 more
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Nov 8, 2022

    T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail

    Recruiting
    • T-cell Lymphoma
    • +30 more
    • Optional Blood Sample
    • Optional Nail Sample
    • Duarte, California
    • +25 more
    Jul 28, 2023

    Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma Trial in Boston (Microdevices, Standard of care therapy, Standard of care

    Recruiting
    • Cutaneous T Cell Lymphoma
    • Peripheral T Cell Lymphoma
    • Microdevices
    • +2 more
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Jul 16, 2022

    T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

    Not yet recruiting
    • T-Cell Non-Hodgkin Lymphoma
    • +14 more
    • WU-CART-007
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jan 17, 2023

    Peripheral T Cell Lymphoma (PTCL), Cell Therapy Trial in United States (MT-101, MT-101 + Conditioning (Lymphodepleting)

    Recruiting
    • Lymphoma, T-Cell, Peripheral
    • +4 more
    • MT-101
    • MT-101 + Conditioning (Lymphodepleting) Chemotherapy
    • Duarte, California
    • +8 more
    Jan 27, 2023

    Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype Trial in Guangzhou (Chidamide combined with CHOP,

    Recruiting
    • Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
    • Guangzhou, Guangdong, China
      Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
    Oct 7, 2022

    Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

    Active, not recruiting
    • Peripheral T Cell Lymphoma
    • Pediatric Hodgkin Lymphoma
    • Brentuximab Vedotin (Genetical Recombination)
    • Tokyo, Japan
      Takeda Selected Site
    Oct 11, 2022